MITOTHERAPEUTIX, LLC

Woodbridge, CT · Founded 2014 · Biotech · Private

siRNA therapeutic targeting MCJ protein to enhance mitochondrial electron transport chain activity in hepatocytes

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · mitotherapeutix.com

Sector: Biotech
Headquarters: Woodbridge, CT
Founded: 2014
Latest Form D: $943K, Dec 2017
Total capital: $4M

Federal grants: $3M; 7 awards · 2017–2023; Rank in peer group#236 of 514
Private capital raised: $973K; 2 Form D · last Dec 2017; 106 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 4 pending

Capital timeline

Latest events

Mar 2023Federal grantHealth and Human S · Phase I · Novel Treatment for Alcohol-associated Liver Disease$274K
Feb 2023Federal grantHealth and Human S · Phase II · A novel approach to treat non-alcoholic steatohepatitis (NASH)$1M
May 2022Federal grantHealth and Human S · Phase II · A novel approach to treat non-alcoholic steatohepatitis (NASH)$860K
May 2021Federal grantHealth and Human S · Phase II · A novel approach to treat non-alcoholic steatohepatitis (NASH)$253K
Sep 2020Federal grantAgriculture · A Novel Therapeutic To Address Fatty Liver In Post-parturient Dairy Cows$31K
Jun 2018Federal grantHealth and Human S · Phase I · A Novel Treatment for Acetominophen-Induced Liver Injury$264K
Dec 2017Private capital raisedForm D · SEC · 2nd filing$943K
Oct 2016Private capital raisedForm D · SEC · 1st filing$30K

Show 1 earlier federal award

Jun 2017Federal grantHealth and Human S · Phase I · A novel approach to treat non-alcoholic steatohepatitis (NASH)$318K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#236 · top 46%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Daniel V. WagnerDirectorNamed in SEC Form D filings
Fenel V. EloiDirectorNamed in SEC Form D filings
John V. TalleyExecutive Officer, DirectorNamed in SEC Form D filings
Robert HemleyExecutive Officer, DirectorNamed in SEC Form D filings
Robert HennesseyExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4

Jun 9, 2022PendingMultivalent Ligand Clusters For Targeted Delivery Of Therapeutic AgentsUSPTOApplication 17300676
PendingMultivalent Ligand Clusters For Targeted Delivery Of Therapeutic AgentsUSPTOApplication PCTUS2020023603
PendingMultivalent Ligand Clusters for Targeted Delivery of Therapeutic AgentsUSPTOApplication 62952607

Show all 4 patent records

Multivalent Ligand Clusters For Targeted Delivery Of Therapeutic AgentsJun 9, 2022 · Application 17300676Pending
Multivalent Ligand Clusters For Targeted Delivery Of Therapeutic AgentsApplication PCTUS2020023603Pending
Multivalent Ligand Clusters for Targeted Delivery of Therapeutic AgentsApplication 62952607Pending
Multivalent Ligand Clusters For Targeted Delivery Of Therapeutic AgentsApplication 62821628Pending

ALLOSTEROS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Atrin PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
PANTHERICS INCORPORATEDSimilar federal contract value in Biotech · null in contracts
VIVACELLE BIO INCSimilar federal contract value in Biotech · null in contracts
FLAG THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Inomagen Therapeutics, IncSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.